Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype

被引:78
作者
Llerena, A [1 ]
Cobaleda, J [1 ]
Martinez, C [1 ]
Benitez, J [1 ]
机构
[1] UNIV EXTREMADURA,FAC MED,SCH MED,DEPT PHARMACOL & PSYCHIAT,E-06071 BADAJOZ,SPAIN
关键词
pharmacogenetics; CYP2D6; debrisoquine; gender; smoking;
D O I
10.1007/BF03190261
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic and environmental factors are determinants of the interindividual and interethnic variability in drug metabolism. The metabolism of several important drugs (e.g. haloperidol) cosegregates with that of debrisoquine. Thus, interethnic differences in debrisoquine hydroxylation polymorphism (CYP2D6) might be partly responsible for the variations in haloperidol disposition between races. The influence of tobacco, ethanol, caffeine, gender, and oral contraceptive use on the debrisoquine metabolic ratio (MR) has been analyzed in 633 Spanish healthy volunteers. MR was also determined in panels of healthy volunteers. 18 smokers were studied during a tobacco abstinence period, and 31 women three times during the same menstrual cycle. Among EMs, debrisoquine MR was significantly (P < 0.05) lower during smoking cessation (mean antilog +/- SD, 0.48 +/- 0.29) compared to a smoking period (0.61 +/- 0.23). During the lutheal phase of the menstrual cycle, debrisoquine MR was also significantly (P < 0.01) lower (0.33 +/- 0.41) compared to the ovulatory-phase (0.41 +/- 0.34) and the phase before ovulation (0.44 +/- 0.36). Among EMs, it is suggested that debrisoquine MR may be modified by tobacco smoking and sexual hormones. The clinical relevance of these findings remains unclear.
引用
收藏
页码:129 / 138
页数:10
相关论文
共 54 条
[41]   POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN [J].
MAHGOUB, A ;
IDLE, JR ;
DRING, LG ;
LANCASTER, R ;
SMITH, RL .
LANCET, 1977, 2 (8038) :584-586
[42]   THE DOPAMINE TRANSPORTER AND CYTOCHROME-P450IID1 (DEBRISOQUINE 4-HYDROXYLASE) IN BRAIN - RESOLUTION AND IDENTIFICATION OF 2 DISTINCT [H-3] GBR-12935 BINDING-PROTEINS [J].
NIZNIK, HB ;
TYNDALE, RF ;
SALLEE, FR ;
GONZALEZ, FJ ;
HARDWICK, JP ;
INABA, T ;
KALOW, W .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 276 (02) :424-432
[43]  
OHNHAUS EE, 1987, CLIN PHARMACOL THER, V41, P246
[44]   EFFECT OF STEROIDS ON THE CYTOCHROME-P4502D6-CATALYZED METABOLISM OF METOPROLOL [J].
PEPPER, JM ;
LENNARD, MS ;
TUCKER, GT ;
WOODS, HF .
PHARMACOGENETICS, 1991, 1 (02) :119-122
[45]   HALOPERIDOL CONCENTRATIONS ELEVATED IN CHINESE PATIENTS [J].
POTKIN, SG ;
SHEN, YC ;
PARDES, H ;
PHELPS, BH ;
ZHOU, DF ;
SHU, LN ;
KORPI, E ;
WYATT, RJ .
PSYCHIATRY RESEARCH, 1984, 12 (02) :167-172
[46]   FREQUENCY OF S-MEPHENYTOIN HYDROXYLATION DEFICIENCY IN 373 SPANISH SUBJECTS COMPARED TO OTHER CAUCASIAN POPULATIONS [J].
REVIRIEGO, J ;
BERTILSSON, L ;
CARRILLO, JA ;
LLERENA, A ;
VALDIVIELSO, MJ ;
BENITEZ, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (06) :593-595
[47]   A FAMILY STUDY OF GENETIC AND ENVIRONMENTAL-FACTORS DETERMINING POLYMORPHIC HYDROXYLATION OF DEBRISOQUIN [J].
STEINER, E ;
ISELIUS, L ;
ALVAN, G ;
LINDSTEN, J ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (04) :394-401
[48]   COMPARISON OF THE PREVALENCE OF THE POOR METABOLIZER PHENOTYPE FOR CYP2D6 BETWEEN 203 HMONG SUBJECTS AND 280 WHITE SUBJECTS RESIDING IN MINNESOTA [J].
STRAKA, RJ ;
HANSEN, SR ;
WALKER, PF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :29-34
[49]  
SYVALAHTI EKG, 1986, BRIT J CLIN PHARMACO, V22, P89
[50]  
VESELL ES, 1977, CLIN PHARMACOL THER, V22, P659